Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
about
Oral and sublingual immunotherapy for food allergyUsing Component-Resolved Diagnostics in the Management of Peanut-Allergic PatientsThe rise of food allergy: Environmental factors and emerging treatmentsA practical view of immunotherapy for food allergyCurrent Options for the Treatment of Food AllergyRecent advances in immunotherapy and vaccine development for peanut allergyFood allergies: the basicsThe rapidly changing world of food allergy in childrenMechanisms of Oral ToleranceIgE antibodies and response to cow's milk elimination diet in pediatric eosinophilic esophagitisDiagnosis and management of food allergies: new and emerging options: a systematic review.2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cellsRandomized trial of peanut consumption in infants at risk for peanut allergyA randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergyDiagnosis and treatment of pediatric food allergy: an update.Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects.Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy.Food allergy and the gut.Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergySuccessful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.Diagnosis, management, and investigational therapies for food allergies.Toward precision medicine and health: Opportunities and challenges in allergic diseasesImproving the safety of oral immunotherapy for food allergy.Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice.The changing geoepidemiology of food allergies.Oral immunotherapy for food allergy: mechanisms and role in management.Peanut immunotherapy.Active management of food allergy: an emerging concept.Oral immunotherapy for the treatment of food allergy.Current opinion and review on peanut oral immunotherapyDeveloping therapies for peanut allergy.The future of biologics: applications for food allergy.Advances in allergen immunotherapy: aiming for complete tolerance to allergens.Current developments for improving efficacy of allergy vaccines.Is clinical tolerance possible after allergen immunotherapy?An Examination of Clinical and Immunologic Outcomes in Food Allergen Immunotherapy by Route of Administration.Food specific oral immunotherapy: a potential treatment for food allergy.
P2860
Q21198709-A7A26547-1D92-444D-A191-E5F1517E4381Q26743517-4EAC8CB0-8D2B-4CE4-9A1E-CCF5B94D178BQ26744294-C03B98F1-4769-44BE-BF57-6B2C016C3B85Q26767047-D6ED2936-C880-461B-A279-F10B9715D875Q26784498-14A170E5-9AD9-4133-819E-EEA97C08E654Q26796442-8BE2EB30-32A7-4684-90EE-CD26E3E9715CQ27011839-87CB4909-03CA-48E1-AC2B-06FFD6755EA8Q27014162-FF93FCD9-2AB1-477D-B187-0935D65E6584Q28082715-2EC9C297-C85E-4E56-AF23-673E3304346CQ30276912-967C5546-60D4-47EF-B264-2EF45933504EQ34446206-48FA436B-E3D4-439D-9AC7-4F6FC0EAD8E3Q34500152-A3039738-24AF-4E0B-A4C3-553EC01358D4Q35348677-0FEE8DF4-2A8B-4D2F-A0C0-ADCD51FF6570Q35559718-129CC998-09B9-4B45-89BD-EAD17392135BQ35603477-C18F9A46-211E-420F-8555-8C53DF06F047Q35604101-6C1BC078-7312-4F1A-9E3C-611C03FB2C4EQ35828399-456F96ED-B104-4D3A-80A6-2E1598F822ADQ35923082-DDFC0926-2B63-4A8F-92DE-A840A73961C0Q35939076-E5FE2DBF-95C0-4918-BE46-0DA43AD11C84Q36144704-E3819CE8-CBE2-40D8-9C6E-D5B76841494CQ36229922-8EB4844D-6A94-46E9-92EF-88DC458552C2Q36520518-499EAD10-453F-41F7-A11B-9DB5805A1D33Q36658984-C76AE3B3-230F-40A8-B7AA-146B92F8FECDQ36692411-D4E347F7-6569-4825-A37C-A8330D405CCCQ36916201-B4B01875-8415-4122-842A-A726C2647156Q37106401-EBDC8F67-AD8C-41FC-AB14-B7F97F4EE38CQ37343952-3515CDD1-DC5B-4C96-821A-ABCBBD0414BDQ38188844-B9F751A9-E405-4563-A8F9-F6BD8D1A02C7Q38235447-E88AA505-E1C9-4184-BF94-D2EA8DA9F73FQ38256162-E91E2A1A-98E0-44E3-870B-7DA6660BE9F0Q38265988-AA6C81A0-73FB-4C22-AA75-58815F240ECDQ38271442-7892CF0A-BF91-40DD-AFB0-3877D5CA4E7FQ38284711-7391AE4F-7BA4-4DA4-B045-003621E1CB28Q38296706-F8C263D2-7BD9-404F-9D58-CE9D1A9ED892Q38348057-46B52951-6583-47F3-B6BB-24FF168E9CC5Q38391526-9CDC6768-AFCC-4AC4-9E59-DF1CD73DC034Q38503330-5EAC8239-51B4-4F61-9C5D-C726C51F4022Q38542313-889DE666-48E5-4EFB-8B43-640C0AE24765Q38542587-58C0F86C-B7DE-4001-A692-B657C10BAB4BQ38543015-7B385755-EB2E-4C78-B1DA-829C414E5E5E
P2860
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@en
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@nl
type
label
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@en
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@nl
prefLabel
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@en
Sustained unresponsiveness to ...... ted peanut oral immunotherapy.
@nl
P2093
P2860
P1476
Sustained unresponsiveness to ...... eted peanut oral immunotherapy
@en
P2093
A Wesley Burks
Amy M Scurlock
Anne Hiegel
Caitlin Burk
Janet Kamilaris
Jelena P Berglund
Lynn Christie
Michael Kulis
Mohamed H Shamji
P Brian Smith
P2860
P304
P356
10.1016/J.JACI.2013.11.007
P407
P577
2013-12-19T00:00:00Z